Skyrizi Injection is commonly used to help with certain chronic conditions presenting with systemic or localized discomfort, such as plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. This medication is used to manage these conditions. The medicine is applied across domains where additional symptomatic support is needed to manage symptoms that become more disruptive during flare-ups.

Skyrizi helps address symptom clusters that may become intense or disrupt daily comfort, such as noticeable physical discomfort and functional strain. It is relevant in contexts marked by increased discomfort or tension, which is applied during phases where the patient experiences significant symptoms related to systemic imbalance. The medication assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

“It provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.”

Quick Fact: Support for Fluctuating Symptoms

Skyrizi is relevant in conditions characterized by periods of heightened symptoms or recurrent manifestations, contributing to easing the overall symptom load during phases when symptoms intensify and temporary assistance in symptom stabilization is important. It offers symptomatic relief that may help patients cope more steadily with difficult episodes.

Regulatory References

1. European Medicines Agency (EMA) Overview

The eligibility profile for Skyrizi Injection (risankizumab-rzaa) is defined strictly by governmental regulatory authorities, detailing populations permitted, restricted, or prohibited from using the medicine.

Approved and Contraindicated Populations

Skyrizi is indicated only in adults (aged 18 years and older) for all approved uses. Safety and effectiveness have not been established in pediatric patients (<18 years), and the medicine is not indicated for this age group. Use in older adults (ge 65 years) is permitted without a required dose adjustment.

The medicine is contraindicated for any patient with a history of a serious hypersensitivity reaction to risankizumab-rzaa or its excipients. It must not be administered to patients with a clinically important active infection, including active tuberculosis (TB).

Conditional Use and Restrictions

Use is restricted for specific groups. Patients must be evaluated for latent TB infection prior to starting therapy. Live vaccines must be avoided during treatment and for a specified period post-therapy. Women of childbearing potential must use an effective method of contraception during and after treatment. Use in pregnant women is generally not recommended. No dose adjustments are considered necessary for patients with renal or hepatic impairment.

Interaction Profile: Live Vaccines and Other Immunosuppressants

Skyrizi (risankizumab) is an interleukin-23 (IL-23) antagonist, a type of biologic medicine that affects the immune system. Because it is an immunosuppressive agent, the primary documented interaction concerns live vaccines.

Interacting Product Category	Official Restriction/Condition
Live Vaccines	Avoid use in patients receiving Skyrizi. Medications that affect the immune system may increase the risk of infection following administration of live vaccines.
Timing Constraint	Prior to initiating Skyrizi, all age-appropriate immunizations should be completed. If a patient has received a live vaccine, an interval of at least 4 weeks is recommended before starting treatment. After stopping treatment, live vaccines should be avoided for at least 21 weeks.

Other Interaction Notes

Risankizumab is a monoclonal antibody and is expected to be degraded into small peptides and amino acids via general catabolic pathways, similar to endogenous immunoglobulins. Therefore, it is not expected to undergo metabolism by hepatic enzymes or renal elimination. This means that clinically significant interactions between Skyrizi and inhibitors, inducers, or substrates of medicinal product metabolizing enzymes, such as cytochrome P450 (CYP) enzymes, are not anticipated and no dose adjustment is necessary.

The safety and efficacy of combining Skyrizi with other immunosuppressive medicines, including other biologics or phototherapy, have not been evaluated in clinical trials.

Targeted Neutralization of Interleukin-23 (IL-23)

Skyrizi is a specialized monoclonal antibody that works by binding directly and selectively to the p19 subunit of the inflammatory protein Interleukin-23 (IL-23). This binding action neutralizes IL-23, physically preventing it from attaching to the specific IL-23 receptor on immune cells. This targeted mechanism is central to the drug's action, as it prevents the initial signal required for the propagation of the IL-23-driven inflammatory cascade.

---

Downstream Disruption of the Th17 Inflammatory Axis

By blocking IL-23, the medicine fundamentally interrupts the IL-23/Th17 axis, which is a core regulatory pathway in the immune system. This intervention halts the cellular communication cascade that leads to the excessive activation and maintenance of pro-inflammatory T helper 17 (Th17) cells. The resulting suppression of this cascade decreases the magnitude of persistent immune signaling within the Th17 axis.

---

Suppression of Pro-Inflammatory Mediators

The disruption of the upstream IL-23 signal results in a reduction in the production and release of key downstream inflammatory messengers, such as Interleukin-17A (IL-17A) and Interleukin-22 (IL-22). This physiological change alters the consequences of excessive mediator activity, contributing to a shift in the inflammatory signaling dynamics and ultimately contributing to the modulation of overactive physiological responses in targeted tissues.

How to Use Skyrizi Injection (Risankizumab-rzaa)

Skyrizi is administered as a parenteral therapy, meaning it is given either as a subcutaneous (SC) injection or as an intravenous (IV) infusion, based on the condition being addressed. The SC route is used for maintenance dosing across all approved indications and for both the initiation and continuation of treatment for plaque psoriasis and psoriatic arthritis. The IV route is reserved exclusively for the initial induction phase of treatment for Crohn's disease and ulcerative colitis.

Official Dosing and Schedule

Treatment is structured in two distinct phases: an initial, more intensive induction phase, followed by a maintenance phase with extended dosing intervals.

Indication	Initial Dose & Route	Maintenance Dose & Schedule
Plaque Psoriasis / Psoriatic Arthritis	150 mg SC (Week 0, Week 4)	150 mg SC every 12 weeks
Crohn's Disease / Ulcerative Colitis	600 mg or 1,200 mg IV Infusion (Weeks 0, 4, 8)	180 mg or 360 mg SC every 8 weeks (starting Week 12)

Administration Requirements

For the SC injection, the prefilled device should be allowed to reach room temperature before administration. In the case of an IV induction, the medication must be diluted by a healthcare professional and infused over a specified duration—at least one hour for the 600 mg dose and at least two hours for the 1,200 mg dose. No dose adjustment is required for older adults or those with renal or hepatic impairment. If a dose is missed, it should be administered as soon as possible, and the regular schedule should then be resumed.

Research evidence / Overview of studies for Skyrizi Injection

Research examining Skyrizi (risankizumab-rzaa) was evaluated in large-scale clinical trials and specialized follow-up studies. These investigations are conducted to understand what changes are measured during defined study periods, which specific groups of patients were involved, and what aspects of the condition were evaluated. The evidence summarized here is derived from studies monitored by official regulatory bodies.

---

Evidence for Use in Plaque Psoriasis Research

Research exploring how symptoms change over time in plaque psoriasis was studied for through multiple large-scale, randomized, controlled Phase 3 trials. These studies compared observed outcomes against both a placebo and other advanced therapeutic agents. Findings describe patterns observed in the studies related to measurements of skin clearance and how symptoms evolved during the initial 16-week phase. Patterns of prolonged observation were then tracked for up to a year. Long-term observation periods extending beyond six years are mainly derived from extension cohorts.

---

Evidence for Use in Psoriatic Arthritis Research

The study base for active psoriatic arthritis (PsA) was evaluated in two pivotal, multi-center Randomized Controlled Trials (RCTs). These studies explored outcomes related to physical discomfort and daily functioning in adults, examining changes in swollen and tender joints (ACR criteria). They also monitored specific outcomes linked to inflammatory or irritative states, such as enthesitis and dactylitis. Findings describe patterns observed at 24 weeks and through follow-up, with results applying to populations including those who had prior exposure to biologic therapies. Limited data exists for certain patient subgroups.

---

Evidence for Use in Inflammatory Bowel Disease Research

Crohn’s Disease Clinical Study Structure

Crohn’s disease was studied for outcomes related to systemic or functional imbalance through a sequence of Randomized Controlled Trials (RCTs) covering short-term induction and maintenance phases. These trials monitored the criteria for clinical remission, which is tracked through patient-reported outcomes for abdominal pain and stool frequency, and through endoscopic assessments of the intestinal lining. A key limitation is that long-term continuous data beyond one year are primarily derived from open-label extension studies.

Ulcerative Colitis Clinical Study Structure

Ulcerative colitis was studied for outcomes related to systemic or functional imbalance in recent Randomized Controlled Trials (RCTs). The trials primarily measured the criteria for clinical remission at 12 weeks and 52 weeks, using standardized tools. Research also explored endoscopic and microscopic outcomes. The evidence base is newer, and long-term effects are not fully established, with follow-up durations limited in the initial controlled trials.

Key Studies & References

1. Induction and maintenance therapy with risankizumab in Crohn's disease: results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
2. Clinical Review Report: Risankizumab (Skyrizi) for Plaque Psoriasis (Including UltIMMA-1, UltIMMA-2, IMMhance, and IMMvent trials)

Common questions about Skyrizi Injection (FAQ)

Q: What happens if a person misses a scheduled dose of Skyrizi Injection?

A: Official prescribing information indicates that administration is recommended as soon as possible after a dose is missed. The regular schedule is then recommended to be resumed. The specific timing for continuing the schedule depends on the approved dosing frequency for the condition being treated.

Q: Can Skyrizi Injection be used during pregnancy or while breastfeeding?

A: Regarding pregnancy, official documents state that it is not known if the medicine can harm an unborn baby. For breastfeeding, it is unknown if the medicine passes into breast milk or what its potential effects may be on a breastfed child.

Q: Is it true that Skyrizi Injection is not approved for all types of psoriasis?

A: Yes, regulatory documents indicate that Skyrizi is specifically approved for the treatment of moderate-to-severe plaque psoriasis in adults. This means its official use is defined for this specific type and severity of psoriasis.

Q: Can Skyrizi Injection be used for psoriatic arthritis?

A: Yes, according to official regulatory documentation, Skyrizi is approved for the treatment of active psoriatic arthritis in adults.

Q: What is the main reason a doctor would prescribe Skyrizi Injection?

A: Skyrizi is indicated as a systemic treatment for certain chronic inflammatory conditions in adults. It functions as an interleukin-23 (IL-23) antagonist, which is a type of medicine that selectively targets a specific pathway involved in persistent inflammation.

Q: How does Skyrizi Injection differ from other injectable treatments for plaque psoriasis?

A: The difference lies in the mechanism of action, which is how the drug works. Skyrizi is a monoclonal antibody that selectively targets the p19 subunit of the inflammatory protein Interleukin-23 (IL-23) to block its signaling pathway.

Q: What conditions besides psoriasis is Skyrizi Injection being studied for?

A: In addition to plaque psoriasis, Skyrizi is approved to treat adults with active psoriatic arthritis and two types of inflammatory bowel disease: moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis.

Q: How quickly do people typically start noticing a difference after starting Skyrizi?

A: The timing of observed changes varies by condition. Clinical response in studies for Crohn's disease was observed as early as Week 4 of the induction phase. For conditions like psoriasis, the main efficacy endpoints in trials are often evaluated at Week 16.

Q: Does Skyrizi Injection have a weight-loss side effect?

A: No, based on the adverse reactions reported during clinical studies, weight loss was not reported as a side effect associated with the use of Skyrizi.

Q: Is it common to feel fatigued after receiving a Skyrizi Injection?

A: Official product information lists fatigue as a common adverse reaction associated with Skyrizi treatment. This indicates that it was a frequently reported event during clinical trials.

Q: Can Skyrizi Injection cause joint pain or muscle aches?

A: Joint pain (arthralgia) and back pain are listed among the common adverse reactions reported in clinical trials, particularly for subjects treated for inflammatory bowel disease.

Q: Are there any long-term side effects associated with Skyrizi that people worry about?

A: Long-term side effects were not identified in studies through 52 weeks of treatment. However, the risk of serious infections and other safety concerns are monitored as part of the official safety profile.

Q: Does Skyrizi Injection increase the risk of getting sick with common colds?

A: Upper respiratory infections, which may include the common cold, are listed as common adverse reactions in the official prescribing information. This risk is related to the medicine's effect on the immune system.

Q: Can Skyrizi Injection be taken at the same time as the flu vaccine?

A: Official prescribing information indicates that live vaccines are restricted by label information in patients receiving Skyrizi. This includes the nasal spray form of the influenza vaccine. Inactivated (non-live) vaccines are not restricted in the same way.

Q: Are there specific foods or supplements that should be avoided while taking Skyrizi?

A: No specific food restrictions are listed in official product documentation. However, official documents advise caution regarding any supplements that are known to significantly affect the immune system.

Q: What is the typical age range of people who are prescribed Skyrizi?

A: The medicine is approved for use only in adults, defined as patients 18 years of age or older.

Q: Do all patients with plaque psoriasis eventually stop responding to Skyrizi?

A: The concept of loss of response is monitored in long-term studies for all advanced therapies. Regulatory documents note that the clinical trials for Skyrizi included patients who had previously experienced loss of response to other advanced treatments.

Q: Does Skyrizi Injection cause headaches or migraines?

A: Headache is listed as a common adverse reaction in the official prescribing information. Migraines are not explicitly listed among the frequently reported adverse events in clinical trials.

Q: How does Skyrizi Injection affect the immune system compared to TNF blockers?

A: Skyrizi affects the immune system by selectively neutralizing Interleukin-23 (IL-23). This is a different pathway compared to TNF blockers, which target Tumor Necrosis Factor (TNF) to achieve their anti-inflammatory effect.

Q: Does Skyrizi Injection interact with common blood pressure medications?

A: The medicine is a monoclonal antibody that is degraded like natural proteins, not metabolized by liver enzymes. For this reason, clinically significant interactions with many common medications, such as blood pressure drugs, are generally not anticipated.

Q: Is Skyrizi Injection known to affect cholesterol levels?

A: Transient elevations in certain lipid parameters, such as total cholesterol, were observed in clinical studies. The official safety profile includes monitoring of these changes.

Q: Are people with inflammatory bowel disease (IBD) eligible for Skyrizi?

A: Yes, Skyrizi is approved to treat adults with moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis, both of which are forms of inflammatory bowel disease (IBD).

Q: Does Skyrizi Injection have any known effect on mental health or mood?

A: Official prescribing information indicates that depression was not reported as an adverse reaction in the clinical trials conducted for the drug.

Q: Are there any required screenings before starting Skyrizi Injection?

A: An evaluation for tuberculosis (TB) infection is a condition for initiating treatment as described in the official label. Additionally, for the inflammatory bowel disease indications, liver enzymes and bilirubin levels are evaluated at the start of therapy.

Q: What clinical trials led to the approval of Skyrizi Injection?

A: The approval of Skyrizi was supported by evidence from large-scale, randomized, controlled Phase 3 trials. For inflammatory bowel disease, specific trials cited in regulatory documents include ADVANCE, MOTIVATE, and FORTIFY.

Q: Is Skyrizi Injection available in different dosage strengths?

A: The medicine is available in different dosage strengths and forms to accommodate the specific needs of the approved conditions. These include prefilled devices for subcutaneous (under the skin) use and vials for intravenous (into the vein) infusion.

Q: How long has Skyrizi Injection been on the market?

A: The original approval date for Skyrizi by the FDA for its first indication was April 23, 2019. Subsequent approvals for other conditions have followed this date.

How to Store and Dispose of Skyrizi Injection?

Skyrizi (risankizumab-rzaa) injection is a biologic medicine that requires specific environmental controls for storage to maintain its stability.

Official Storage Requirements

Condition	Requirement
Temperature	Store in a refrigerator between 2 C and 8 C (36 F and 46 F).
Prohibited	Must not be frozen and must not be shaken.
Light Protection	Keep in the original carton to protect from light until use.
Child Safety	Store out of the sight and reach of children.
Stability	The injection may be stored out of refrigeration for a single period of up to 24 hours at temperatures up to 25 C (77 F).

Official Disposal Instructions

Used Skyrizi pre-filled pens and syringes are considered sharps waste. They must be placed immediately into an FDA-cleared sharps disposal container.

Used injection devices are prohibited from being disposed of in household trash or down the drain. The filled sharps container must be disposed of according to local community guidelines.